Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline
October 06, 2020 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when...
Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer
October 01, 2020 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis
September 29, 2020 07:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome...
Kaleido Biosciences to Present at Upcoming September Investor Conferences
September 09, 2020 07:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming...
Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress™ (EASL)
August 27, 2020 07:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic...
Kaleido Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference
August 05, 2020 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 07:35 ET
|
Kaleido Biosciences
- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 - LEXINGTON, Mass.,...
Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19
July 23, 2020 07:00 ET
|
Kaleido Biosciences
- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences,...
Kaleido Biosciences Announces CEO Leadership Transition
June 16, 2020 16:45 ET
|
Kaleido Biosciences
- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter - The Board of Directors has established an Office of the CEO to manage the company through...
Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
June 08, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...